H002 in Patients With EGFR Mutation Locally Advanced or Metastatic NSCLC
Status:
Recruiting
Trial end date:
2025-02-28
Target enrollment:
Participant gender:
Summary
This is a phase I/IIa, open-label, dose-escalation and expansion study to evaluate the
safety, tolerability, PK and preliminary anti-tumor activity of H002 when given orally in
patients with EGFR mutation-positive locally advanced or metastatic non-small cell lung
cancer (NSCLC).
The study will contain two parts: Part A is dose escalation phase (i.e., Phase I) and Part B
is dose expansion phase (i.e., Phase IIa).